SAN DIEGO , May 4, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and Circulating Tumor Cells (CTCs), today announced that the Company will issue its financial results for the first
Announces Increased Revenues and Strong Year-over-Year Growth in Test Volume Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO , May 12, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the
SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, announces that President and CEO Michael Nall is scheduled to present a corporate overview at the LD Micro
Clinical utility and clinical validation of CTCs and ctDNA to analyze cancer biomarkers ALK, ROS1 and EGFR demonstrated SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (Nasdaq:BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of
Expands patent protection for liquid biopsy platform SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (Nasdaq: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, today announced receipt of a U.S.
SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, today announced that it has entered into a clinical collaboration with Sarah Cannon Research Institute (SCRI),
SAN DIEGO --(BUSINESS WIRE)-- Biocept , Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, today announced the launch of its FGFR1 amplification testing utilizing a patient's blood sample.
SAN DIEGO --(BUSINESS WIRE)-- Biocept , Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, today announced that President and Chief Executive Officer Michael Nall will participate in a panel
New test provides physicians with a liquid biopsy option to reach informed treatment decisions for patients with melanoma and other tumors SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the
Discussion to Feature Applications of Liquid Biopsies to Identify PDL-1 and CMET Expression in Lung Cancer SAN DIEGO --(BUSINESS WIRE)-- Biocept , Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer,
